EUVIMEDEUVIMED entdecken
Crossref

Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling

Rohan Bhadange, Anil Bhanudas Gaikwad

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04870-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Rohan Bhadange und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India. Hauptthemen laut MEDLINE: rho-Associated Kinases, Kidney, Risedronic Acid, Kidney Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Anusandhan National Research Foundation (ANRF) [earlier Science and Engineering Research Board (SERB)], Department of Science and Technology, Govt. of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a global health concern with rising morbidity and mortality. The repurposing of drugs offers a valuable opportunity to accelerate therapeutic development in CKD. Risedronate (RIS), a nitrogen-containing bisphosphonate approved to prevent and treat bone-related conditions, has therapeutic potential in CKD. Hence, we aimed to investigate the potential of RIS in unilateral ureteral obstruction (UUO)-induced renal fibrosis in Sprague-Dawley (SD) rats and recombinant human-transforming growth factor-β1 (rh-TGF-β1)-induced fibrosis in normal rat kidney epithelial cells (NRK-52E). Following randomization, animals were subjected to sham, UUO, and UUO + RIS (5 µg/kg, s.c., twice weekly) for 21 days. Post-treatment, plasma, urine, and kidney tissue samples were collected for subsequent biochemical, histological, and immunohistochemical analysis. Additionally, NRK-52E cells were divided into a normal control (NC), rh-TGF-β1, and rh-TGF-β1 + RIS (10 µM) groups for 48 h, and cell samples were harvested for cell viability, cell morphology, and immunocytochemistry assay. RIS treatment notably restored the kidney mass ratio and kidney function parameters, and histopathological studies showed that RIS significantly preserved the kidney structure in UUO rats. While RIS treatment notably suppresses the levels of FPPS, p-NF-κB, TNF-α, IL-6, TGF-β, and CTGF, as well as collagen and fibronectin, as proven by immunohistochemistry, ELISA, and qRT-PCR in UUO rats. Moreover, immunocytochemistry suggested that RIS inhibits protein prenylation-dependent expression of p-ERK 1/2, RhoA, and ROCK1 in NRK-52E cells. Indeed, the study findings indicated that RIS treatment modulated renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling axis, holding the clinical promise in CKD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesKidneyRisedronic AcidKidney DiseasesRenal Insufficiency, ChronicAnimalsFibrosisNF-kappa BRats, Sprague-DawleyMaleUreteral ObstructionRatsrhoA GTP-Binding ProteinCell LineSignal TransductionTransforming Growth Factor beta1MAP Kinase Signaling SystemExtracellular Signal-Regulated MAP Kinasesrho GTP-Binding Proteins

Stichwörter der Autor:innen

CKDDrug repurposingERK/NF-κBKidney fibrosisProtein prenylationRhoA/ROCK1

Substanzen

NF-kappa Brho-Associated KinasesrhoA GTP-Binding ProteinRisedronic AcidROCK1 protein, ratTransforming Growth Factor beta1RhoA protein, ratExtracellular Signal-Regulated MAP Kinasesrho GTP-Binding Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India.
  • Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India. anil.gaikwad@pilani.bits-pilani.ac.in.

Förderung

  • Anusandhan National Research Foundation (ANRF) [earlier Science and Engineering Research Board (SERB)], Department of Science and Technology, Govt. of India

Zitieren

APA

Bhadange, R., & Gaikwad, A. B. (2025). Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04870-w

Vancouver

Bhadange R, Gaikwad AB. Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04870-w

BibTeX
@article{Bhadange2025,
  author = {Bhadange, Rohan and Gaikwad, Anil Bhanudas},
  title = {Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04870-w}
}
Kostenlos starten →